Exosomes Suppliers & Manufacturers
Identifiers
Functions
What does available trade activity indicate for Exosomes?
Exosomes is classified under HS Code 3002.12. This falls under Chapter 30: Pharmaceutical products, specifically Heading 3002 (Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc), under subheading: Blood, human or animal, antisera, other blood fractions and immunological products; antisera and other blood fractions.
* The data below is specific to the HS code, not the ingredient.
Suppliers
61
Across 24 countries
Shipments
421
from 2018 to 2026
Total weight
16.9M kg
1,830 TEU · standard 20-foot container units
Last shipment
6 months ago
Last updated at Feb 25, 2026
Growth
↑ 33%
Trade under 3002.12 has increased by 33% over the past 6 months
What does trade activity suggest about the exosomes supply chain?
Trade activity under HS 3002.12 indicates a supply chain dominated by large plasma fractionators and diagnostic companies, with 61 suppliers and 421 shipments over the observed period. The presence of logistics providers and distributors among top shippers suggests the data reflects broader blood-fraction trade flows rather than exosome-specific manufacturing. Business implication: sourcing exosomes through this classification would require verifying whether suppliers actually produce or handle exosome materials, as the signal is indirect and likely includes antisera, immunoglobulins, and other blood products. This limits its use for direct exosome procurement planning.
What does the HS or HTS classification include, and where are its limits for exosomes?
HS code 3002.12 covers antisera and other blood fractions, including human or animal blood products and immunological products, but does not specifically list exosomes or extracellular vesicles. The classification scope is broad, encompassing plasma-derived therapeutics, diagnostics, and related biological materials. Its limits for exosomes are significant: the code cannot distinguish exosome-containing shipments from other blood fractions, and the match method used to associate this code with exosomes carries inherent uncertainty. Formulation or regulatory decisions based on this classification should treat it as a proxy for potential exosome activity, not as confirmed evidence of exosome-specific trade.
Which suppliers are associated with Exosomes trade?
| Supplier | Shipments | Top customer | Growth | Last shipment | |
|---|---|---|---|---|---|
No suppliers found. | |||||
How concentrated or diversified does the supplier landscape appear for exosomes?
The supplier landscape appears moderately concentrated, with a few large players dominating shipment volumes. CSL Behring (Australia) and Ortho Clinical Diagnostics (UK) account for 79 and 53 shipments respectively, while most of the 61 suppliers have fewer than 10 shipments. This suggests a core of high-volume suppliers surrounded by a long tail of smaller or occasional shippers. The presence of major plasma fractionators like Grifols, Octapharma, and Bio Products Laboratory indicates consolidation among established biological product manufacturers. Business implication: for exosome sourcing, this structure suggests limited direct supplier options, and the concentration in blood-fraction trade may not translate to exosome-specific capability.
Which supply risks or dependencies around exosomes require further diligence?
Key supply risks include the inability to confirm exosome-specific content in shipments under HS 3002.12, as the classification covers multiple blood fractions. The presence of logistics providers and distributors among top shippers raises the risk that trade data reflects intermediaries rather than actual exosome manufacturers. Additionally, several suppliers are diagnostic or general pharmaceutical companies, making it uncertain whether their products contain exosomes. Further diligence should focus on obtaining product-level documentation, verifying cold-chain handling capabilities, and confirming whether suppliers have exosome-specific manufacturing or purification processes. Regulatory risk also exists if exosome products are misclassified under this broad blood-fraction code.
Which sourcing geographies and trade lanes appear most relevant to exosomes?
The most relevant sourcing geographies are the United Kingdom, Australia, New Zealand, Belgium, Spain, Mongolia, and the Netherlands, which together account for the majority of shipments and suppliers. The UK leads with 6 suppliers and 85 shipments, while Australia shows high shipment volume from a single supplier (CSL Behring). Trade lanes appear concentrated among established pharmaceutical and diagnostics hubs, with notable activity from Europe and Oceania. Business implication: these regions likely represent established blood-fraction supply networks, but exosome-specific sourcing would require additional verification of product content, as the lanes reflect broader biological product movement rather than confirmed exosome trade.
Which countries drive Exosomes trade activity?
By shipment count
United Kingdom
85 shipments
6 suppliers
3.9M kg total weight
Australia
79 shipments
1 suppliers
599.9K kg total weight
New Zealand
46 shipments
4 suppliers
687.8K kg total weight
Belgium
35 shipments
7 suppliers
302.6K kg total weight
Spain
35 shipments
6 suppliers
1.8M kg total weight
Mongolia
31 shipments
2 suppliers
1.7M kg total weight
Netherlands
29 shipments
2 suppliers
3.6M kg total weight
Argentina
15 shipments
4 suppliers
832K kg total weight
Brazil
14 shipments
4 suppliers
1M kg total weight
Canada
14 shipments
4 suppliers
805.9K kg total weight